138 related articles for article (PubMed ID: 38542262)
1. Redox mechanisms in autoimmune thyroid eye disease.
Buonfiglio F; Ponto KA; Pfeiffer N; Kahaly GJ; Gericke A
Autoimmun Rev; 2024 May; 23(5):103534. PubMed ID: 38527685
[TBL] [Abstract][Full Text] [Related]
2. The Role of Fibrogenesis and Extracellular Matrix Proteins in the Pathogenesis of Graves' Ophthalmopathy.
Chiu HI; Wu SB; Tsai CC
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542262
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
4. Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves' Ophthalmopathy.
Virakul S; Somparn P; Pisitkun T; van der Spek PJ; Dalm VASH; Paridaens D; van Hagen PM; Hirankarn N; Palaga T; Dik WA
Front Endocrinol (Lausanne); 2020; 11():619989. PubMed ID: 33658982
[TBL] [Abstract][Full Text] [Related]
5. Molecular biomarkers of Graves' ophthalmopathy.
Longo CM; Higgins PJ
Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.
Ekronarongchai S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
Thyroid; 2021 Oct; 31(10):1566-1576. PubMed ID: 34235979
[No Abstract] [Full Text] [Related]
7. The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications.
Hung CT; Tsai YW; Wu YS; Yeh CF; Yang KC
J Biomed Sci; 2022 Sep; 29(1):63. PubMed ID: 36050716
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review on the Role of Antioxidants in Thyroid Eye Disease.
Akbarian S; Chaibakhsh S; Kashkouli MB; Karimi N; Abdolalizadeh P; Ghahvehchian H
J Curr Ophthalmol; 2022; 34(1):16-24. PubMed ID: 35620378
[TBL] [Abstract][Full Text] [Related]
9. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
[TBL] [Abstract][Full Text] [Related]
10. Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves' Ophthalmopathy.
Wang Y; Ma XM; Wang X; Sun X; Wang LJ; Li XQ; Liu XY; Yu HS
Front Endocrinol (Lausanne); 2021; 12():788535. PubMed ID: 35069441
[TBL] [Abstract][Full Text] [Related]
11. The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy.
Hou TY; Wu SB; Kau HC; Tsai CC
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944687
[TBL] [Abstract][Full Text] [Related]
12. Effect of Pirfenidone on TGF-β1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Graves' Ophthalmopathy.
Wu SB; Hou TY; Kau HC; Tsai CC
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680057
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
